EPISODE · May 29, 2026 · 10 MIN
May 28, 2026 | GSK/Ionis Bepirovirsen Achieves 19% Functional Cure in Hepatitis B
from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group
Bepirovirsen hits 19% functional cure rate in Phase 3 chronic HBV trials — a first for a disease affecting 300 million. Plus Spero's 245% surge on tebipenem, AstraZeneca's Imfinzi NMIBC approval, CVS restoring Lilly obesity drug coverage, BridgeBio LGMD data, Kardigan IPO plans, and ASCO 2026 abstracts drop.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, bepirovirsen, GSK, Ionis, hepatitis B, functional cure, Spero Therapeutics, tebipenem, oral carbapenem, cUTI, CVS, Eli Lilly, Zepbound, Foundayo, obesity drugs, AstraZeneca, Imfinzi, durvalumab, bladder cancer, NMIBC, BridgeBio, BBP-418, LGMD, muscular dystrophy, Kardigan Therapeutics, MyoKardia, Secretome Therapeutics, Duchenne, ASCO 2026, Trump drug pricing, MFN, Akeso, Novo Nordisk, Merck, BioNTech, Moderna, Lilly, Sanofi, BMS
What this episode covers
Bepirovirsen hits 19% functional cure rate in Phase 3 chronic HBV trials — a first for a disease affecting 300 million. Plus Spero's 245% surge on tebipenem, AstraZeneca's Imfinzi NMIBC approval, CVS restoring Lilly obesity drug coverage, BridgeBio LGMD data, Kardigan IPO plans, and ASCO 2026 abstracts drop.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, bepirovirsen, GSK, Ionis, hepatitis B, functional cure, Spero Therapeutics, tebipenem, oral carbapenem, cUTI, CVS, Eli Lilly, Zepbound, Foundayo, obesity drugs, AstraZeneca, Imfinzi, durvalumab, bladder cancer, NMIBC, BridgeBio, BBP-418, LGMD, muscular dystrophy, Kardigan Therapeutics, MyoKardia, Secretome Therapeutics, Duchenne, ASCO 2026, Trump drug pricing, MFN, Akeso, Novo Nordisk, Merck, BioNTech, Moderna, Lilly, Sanofi, BMS
NOW PLAYING
May 28, 2026 | GSK/Ionis Bepirovirsen Achieves 19% Functional Cure in Hepatitis B
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m